Risk/Benefit Analysis and Therapy Selection in the Age of Expanding DMD Choices in MS
A CME/CE-certified Symposium in conjunction with the 2016 Annual Meeting of the CMSC



Registration Statement


By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements below.


Registration

  VenueCityStateDate
View Agenda  Gaylord National Convention Center
Room Name: Cherry Blossom Ballroom, Level 2
National HarborMD Friday
Jun 3, 2016 5:30 PM


Presentation Slides:


Download (PDF) Click here to view the presentation slides from this symposium.

Click here to view the presentation slides from this symposium. (Coming Soon)

Program Description:

The diagnosis and management of multiple sclerosis continue to evolve at a rapid rate. New disease-modifying drugs – with unique mechanisms of action, differing efficacy rates, and widely varying adverse-event profiles – continue to emerge. A great deal of information on biomarkers and prognostic indicators has also recently emerged, while the diagnostic criteria and categorizations of MS disease continue to change. All of these ongoing shifts make it difficult for busy clinicians to stay up to date with the emerging management information needed to provide the best care for their MS patients.

The educational activity, Risk/Benefit Analysis and Therapy Selection in the Age of Expanding DMD Choices in MS, will provide clinicians with information on the latest advances in MS diagnosis and management and will enable them to individualize care and optimize outcomes for their patients with MS.

Agenda:

Registration: 5:30-6:00 pm
CME/CE Program: 6:00-7:30 pm
  1. Welcome and Introductions
  2. Improving Early Diagnosis in MS
  3. Individualizing DMD Therapy in MS
  4. Incorporating Biomarker and Risk Factors into MS Management
  5. Panel Discussion and Q&A Session
  6. Practice Pearls and Concluding Remarks

Target Audience:

This activity is intended for MS specialists, neurologists, nurses, and other health care professionals who manage patients with MS.

Educational Objectives:

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Incorporate MRI criteria and other prognostic measures to improve diagnosis and initiate DMD therapy earlier in the course of MS
  • Develop individualized MS treatment plans based on an understanding of the mechanisms of action and efficacy and safety profiles of current and emerging DMD therapies
  • Integrate evidence from recent clinical trials on prognostic indicators and biomarkers to improve early diagnosis and prognosis, improve monitoring of disease activity, and guide treatment decisions

Program Faculty

Suhayl Dhib-Jalbut, MD
Professor and Chairman, Departments of Neurology
Rutgers–New Jersey Medical School and
Rutgers–Robert Wood Johnson Medical School
Chief, Neurology Service
Robert Wood Johnson University Hospital
New Brunswick, NJ

Andrew D. Goodman, MD
Professor of Neurology
Chief of the Neuroimmunology Unit
Director of the Multiple Sclerosis Center
University of Rochester
Rochester, NY

Robert T. Naismith, MD
Associate Professor of Neurology
Washington University
St. Louis, MO

The CMSC and NPA do not certify this program for Continuing Education Credit and do not take responsibility for the quality or evidence upon which the content has been based or the faculty chosen.

Accreditation:

Physicians – This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Nurses – Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.


Designation Statement:


Physicians – The Potomac Center for Medical Education designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email contact@potomacme.org.

Nurses – This educational activity for 1.50 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

For information about the nursing accreditation of this program, please contact Global at inquire@globaleducationgroup.com or 303-395-1782.

Disclosure Information


Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias. 

Faculty Disclosures


The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Suhayl Dhib-Jalbut, MDConsultant: Bayer, Biogen, EMD Serono, Teva

Aaron E. Miller, MD Consultant: Acorda, Biogen Idec, EMD Serono, GlaxoSmith Kline, Merck Serono, Nuron Biotech , Sanofi-Aventis, Teva Neuroscience; Consultant/Research Support: Acorda, Biogen Idec , Genentech, Genzyme, Novartis, Ono Pharmaceutical, Roche, Sanofi-Aventis

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Matthew Horn, MD; Bradley Pine; Blair St. Amand; Jay Katz, CCMEP; Dana Simpler, MD: Nothing to Disclose


FDA Disclosure

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses. 


Method of Participation


To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME/CE certificate will be emailed within 2 weeks upon submission of a completed evaluation form.

There is no fee associated with this program.


Special Services


Event staff will be glad to assist you with any special needs. Please email specialservices@rockpointe-pcme.com at least 5 days prior to the program.  

PROVIDED By


Jointly provided by Potomac Center for Medical Education and Rockpointe


      

Jointly provided by Global Education Group and Rockpointe


      

SUPPORTED BY


This program is supported by independent educational grants from Biogen and Teva Pharmaceuticals.



Registration

  VenueCityStateDate
View Agenda  Gaylord National Convention Center
Room Name: Cherry Blossom Ballroom, Level 2
National HarborMD Friday
Jun 3, 2016 5:30 PM